Share This Author
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
These features of HMGB1 are discussed and recent advances that have led to the preclinical development of therapeutics that modulateHMGB1 release and activity are summarized.
The Beclin 1 network regulates autophagy and apoptosis
New findings regarding the organization and function of the Beclin 1 network in cellular homeostasis are summarized, focusing on the cross-regulation between apoptosis and autophagy.
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion
It is demonstrated that HMGB1 is an early mediator of injury and inflammation in liver I/R and implicates TLR4 as one of the receptors that is involved in the process.
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
This immunotherapeutic approach can result in marked tumor regression in some patients for whom no other effective therapy is available at present, and determining its ultimate role in cancer therapy awaits further attempts to increase the therapeutic efficacy of treatment and decrease its toxicity and complexity.
HMGB1 in health and disease.
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
There continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes, so it is important to update guidelines for monitoring autophagic activity in different organisms.
PAMPs and DAMPs: signal 0s that spur autophagy and immunity
Recent advances in the understanding of autophagic molecular mechanisms and functions in emergent immunity are reviewed.
Endogenous HMGB1 regulates autophagy
HMGB1 displaces Bcl-2 from Beclin1 to induce and sustain autophagy in response to cell stress.
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
Preliminary results of the systemic administration of autologous lymphokine-activated killer (LAK) cells and the recombinant-derived lymphokin interleukin-2 to patients with advanced cancer are described, based on animal models in which this regimen mediated the regression of established pulmonary and hepatic metastases from a variety of murine tumors in several strains of mice.
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
- S. Rosenberg, B. S. Packard, C. Seipp
- Medicine, BiologyNew England Journal of Medicine
- 22 December 1988
It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells.